Psilocybin shows promise in treating major depression, often providing relief through immersive experiences in controlled settings. While microdosing is discussed, it appears less impactful compared to higher doses administered during clinical sessions. The underlying mechanisms involve neuroplasticity and a complex interplay of neurotransmitters, suggesting that individual responses to psychedelics may vary significantly.
